查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2030 年筆式注射器市場預測：按類型、劑量、治療、配銷通路、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1383444

到 2030 年筆式注射器市場預測：按類型、劑量、治療、配銷通路、最終用戶和地區進行的全球分析

Pen Injectors Market Forecasts to 2030 - Global Analysis By Type (Disposable and Reusable), Dosage (Fixed Dosage, Variable Dosage, Half-Unit Dosage, Specialized Dosage and Other Dosages), Therapy, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球筆式注射器市場規模為 488.2 億美元，預計在預測期內年複合成長率為 9.2%，到 2030 年將達到 758.1 億美元。

筆式注射器是醫療設備，旨在為患者給藥精確劑量的藥物。它通常用於自行注射各種類型的藥物，例如胰島素、生長激素、某些生物製藥和其他注射。筆式注射器廣泛被患有糖尿病、多發性硬化症和類風濕性關節炎等慢性疾病的患者使用。筆式注射器的設計易於使用，使患者能夠輕鬆處理和給藥，而無需專業的醫療幫助。

Caspersen等人的數據顯示，2020年美國約有1,090萬65歲及以上的人被診斷出患有糖尿病，預計到2050年將達到2,670萬人。

生物製藥的進展

由於其複雜的分子結構和作用機制，生物製藥通常需要精確的給藥。筆式注射器適用於生物製藥，因為它們旨在提供準確和穩定的給藥。筆式注射器還允許患者自我給藥生物製藥製劑，從而減少頻繁前往醫療機構的需要。此外，筆式注射器的便利性和易用性提高了患者對處方生物製藥的依從性和醫囑遵從性，從而推動了市場需求。

與某些藥物的相容性有限

如果筆式注射器與多種藥物不相容，醫療保健提供者可能會猶豫是否開立或推薦筆式注射器。需要多種藥物的患者可能會發現使用不同的給藥方法既不方便又麻煩，因為有些藥物與筆式注射器不相容。這可能會導致患者滿意度和依從性降低。製造商可能會錯失與製藥公司的商機。這可能會導致失去合作夥伴關係和合約。

與數位健康解決方案整合

筆式注射器和數位健康解決方案的整合為患者和醫療保健提供者提供了多種好處和應用。這使得患者能夠追蹤和監控他們的藥物劑量。數位健康平台可以向患者發送提醒和警報，提醒他們按規定時間服藥。根據收集的資料，醫療保健提供者可以就滴定和調整藥物劑量做出資訊的決定，以最佳化治療結果。此外，它還透過提高患者參與度、減少住院率和提供對特定症狀的洞察來促進市場成長。

與替代藥物輸送的競爭

替代藥物傳遞方法為患者提供了多種選擇，包括口服錠劑、吸入器、貼劑，甚至智慧藥丸和植入式設備等新技術。有些患者可能更喜歡替代的藥物輸送方法而不是筆式注射器，因為他們害怕針頭。此外，根據您的症狀，吸入或口服藥物可能比注射藥物更好。此外，技術創新和替代方案的改進對患者和醫療保健提供者越來越有吸引力，阻礙了市場成長。

COVID-19 的影響

筆式注射器市場是醫療設備產業的一部分，在大流行期間可能會經歷正面和負面的影響。大流行期間遠端醫療和遠端監測的興起可能影響了筆式注射器的採用，以幫助慢性病的自我給藥和遠端監測。經濟不確定性和醫療保健優先事項的轉變可能導致市場整合。這種流行病正在影響疫苗接種率和新流感病毒株的出現。

預計糖尿病領域在預測期內將是最大的領域。

糖尿病領域預計將出現良好的成長。筆式注射器可以準確且精確地給藥胰島素，確保個人獲得正確劑量的藥物。筆式注射器結構緊湊、重量輕且易於攜帶，對於需要在旅途中給藥胰島素的人來說非常方便。由於它使用細規格針頭，因此注射過程中的疼痛和不適較少。其易用性、可客製化的給藥和謹慎的給藥正在推動這一領域的需求。

預計居家照護產業在預測期內年複合成長率最高。

由於其便利性和有效性，預計家庭護理設置行業在預測期內將實現最高的年複合成長率。筆式注射器的設計易於使用，並且通常具有簡單的裝載和給藥機制。結構緊湊、便於攜帶，患者可以在家中或旅途中給藥。這使得患者能夠管理自己的藥物治療。這些因素正在推動該細分市場的成長。

比最大的地區

由於慢性病的增加和醫療保健支出的增加，預計亞太地區在預測期內將佔據最大的市場佔有率。中國、日本、印度、韓國和澳洲等國家由於人口眾多且多樣化，成為醫療保健產品和設備的主要市場。賽諾菲、諾和諾德和太陽製藥等主要企業都位於該地區。此外，亞太地區的多個政府已實施政策和舉措來促進先進醫療設備的使用，這對筆式注射器市場產生了積極影響。

複合年複合成長率最高的地區：

由於慢性病的增加、自我給藥的趨勢以及筆式注射器技術的進步，預計北美在預測期內將呈現最高的年複合成長率。糖尿病盛行率的增加和肥胖人口的增加正在推動市場的成長。幾家主要企業在這個市場上競爭，包括 Antares Pharma 和 Becton, Dickinson & Company。此外，技術進步、廣泛的分銷網路的存在以及需要更安全的輸送設備的老年人口的增加是推動北美市場的其他因素。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球筆式注射器市場：按類型

  • 一次性的
  • 可重複使用的

第6章 全球筆式注射器市場：按劑量

  • 固定劑量
  • 可變給藥
  • 半單位給藥
  • 特殊給藥
  • 其他劑量

第7章 全球筆式注射器市場：依處理方式

  • 糖尿病
    • 胰島素
    • 胰高血糖素樣勝胜肽-1 (GLP-1)
  • 生長激素
  • 骨質疏鬆症
  • 生育能力
  • 關節炎
  • 癌症
  • 多發性硬化症
  • 自體免疫疾病
  • 過敏反應
  • 心血管疾病
  • 其他治療方法

第8章 全球筆式注射器市場：按配銷通路

  • 醫院藥房
  • 零售藥房
  • 網路商城
  • 藥局

第9章 全球筆式注射器市場：依最終用戶分類

  • 家庭護理設置
  • 醫院和診所

第10章 全球筆式注射器市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章公司簡介

  • AstraZeneca
  • Becton, Dickinson and Company
  • Merck Group
  • Pfizer Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Sanofi
  • Novo Nordisk A/S
  • Biocon
  • Medtronic
  • Terumo Medical Corporation
  • Sun Pharmaceutical Industries Limited
  • GlaxoSmithKline PLC
  • Mylan NV
  • Novo Nordisk
  • Owen Mumford Limited
  • Phillips-Medisize
Product Code: SMRC24293

According to Stratistics MRC, the Global Pen Injectors Market is accounted for $48.82 billion in 2023 and is expected to reach $75.81 billion by 2030 growing at a CAGR of 9.2% during the forecast period. Pen injectors are medical devices designed to administer precise doses of medication to patients. They are often used for self-injection of various types of medication, including insulin, growth hormones, certain biologic drugs, and other injectables. Pen injectors are widely used by patients with chronic conditions such as diabetes, multiple sclerosis, rheumatoid arthritis, and more. They are designed to be user-friendly, making them easy for patients to handle and administer their medication, even without professional medical assistance.

According to Caspersen et al, in 2020, about 10.9 million people aged above 65 years were estimated to have been diagnosed with diabetes in the U.S, and this number is projected to reach 26.7 million by 2050.

Market Dynamics:

Driver:

Increasing advancements in biologic therapies

Biologic therapies often require precise dosages due to their complex molecular structures and mechanisms of action. Pen injectors are designed to deliver accurate and consistent dosages, making them well-suited for biologic medications. Also, Pen injectors enable patients to self-administer their biologic therapies, reducing the need for frequent visits to healthcare facilities. Additionally, the convenience and ease of use associated with pen injectors can lead to improved patient compliance and adherence to prescribed biologic therapies which fuels the market demand.

Restraint:

Limited compatibility with certain medications

Healthcare providers may be hesitant to prescribe or recommend pen injectors if they are not compatible with a wide range of medications. Patients who require multiple medications, some of which are not compatible with the pen injector, may find it inconvenient or burdensome to use different administration methods. This can lead to decreased patient satisfaction and compliance. Manufacturers may miss out on business opportunities with pharmaceutical companies. This could result in lost partnerships and contracts.

Opportunity:

Integration with digital health solutions

Pen injector's integration with digital health solutions offers a range of benefits and applications for both patients and healthcare providers. It allows patients to track and monitor their medication doses. Digital health platforms can send reminders and alerts to patients, prompting them to take their medication at the prescribed times. Based on the data collected, healthcare providers can make informed decisions about medication titration or adjustments to optimize treatment outcomes. Further, it also enhances patient engagement, reduces hospitalizations, and provides insights for specific conditions which boost the market growth.

Threat:

Competition from alternative drug delivery methods

Alternative drug delivery methods, such as oral tablets, inhalers, patches, and even newer technologies like smart pills or implantable devices, offer patients a range of options. Some patients may prefer alternative methods of drug delivery over pen injectors with a fear of needles. Further, certain conditions may respond better to inhalable or oral forms of medication compared to injectables. Additionally, innovation and improvements in alternative methods, making them more attractive to patients and healthcare providers which impedes the market growth.

COVID-19 Impact

The pen injectors market, which is a part of the medical device industry, likely experienced both positive and negative effects during the pandemic. The rise of telemedicine and remote monitoring during the pandemic may have influenced the adoption of pen injectors, as they are conducive to self-administration and remote monitoring of chronic conditions. Economic uncertainty and shifts in healthcare priorities may have led to market consolidation. The epidemic has affected the vaccination rates, and the emergence of new variants.

The diabetes segment is expected to be the largest during the forecast period

The diabetes segment is estimated to have a lucrative growth. Pen injectors allow for precise and accurate dosing of insulin, ensuring that individuals receive the correct amount of medication. Pen injectors are compact, lightweight, and easy to carry, making them convenient for individuals who need to administer insulin on the go. They use fine-gauge needles, which can result in less pain and discomfort during injection. Its user-friendly nature, customizable dosing and discreet administration propels the segment demand.

The home-care settings segment is expected to have the highest CAGR during the forecast period

The home-care settings segment is anticipated to witness the highest CAGR growth during the forecast period, due to its convenience and effectiveness. Pen injectors are designed to be user-friendly, often featuring simple mechanisms for loading and administering medication. They are compact and portable, allowing patients to administer their medication at home or on the go. It empowers patients to take control of their own medication regimen. These aspects accelerate the segment growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to increasing prevalence of chronic diseases and rising healthcare expenditure. Countries like China, Japan, India, South Korea and Australia are major markets for healthcare products and devices due to their large and diverse population. The region has the presence of major key players such as Sanofi, Novo Nordisk and Sun Pharmaceutical Industries. Additionally, some governments in the Asia Pacific region have implemented policies and initiatives to promote the use of advanced medical devices, which has positively impacted the market for pen injectors.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the increasing prevalence of chronic diseases, the trend towards self-administration of drugs, and advancements in pen injector technology. Increasing incidence of diabetes and growing obese population is contributing toward market growth. The market is competitive with several key players such as Antares Pharma and Becton, Dickinson & Company. Further, technological advancements, the presence of a wide distribution network and increase in geriatric population, which require safer delivery devices, are other factors driving the North America market.

Key players in the market

Some of the key players profiled in the Pen Injectors Market include: AstraZeneca, Becton, Dickinson and Company, Merck Group, Pfizer Inc., Eli Lilly and Company, Novartis AG, Sanofi, Novo Nordisk A/S, Biocon, Medtronic, Terumo Medical Corporation, Sun Pharmaceutical Industries Limited, GlaxoSmithKline PLC, Mylan N.V., Novo Nordisk, Owen Mumford Limited and Phillips-Medisize.

Key Developments:

In February 2023, Phillips-Medisize announced an addition to its portfolio of drug delivery devices, with its pen injector platform that is described as being more affordable to produce. The pen injector has been designed to match user expectation and experiences with disposable pen products, the company added.

In January 2023, Sun Pharmaceutical Industries Ltd launched its Phenobarbital sodium injection, SEZABY for treatment of neonatal seizures in the US. SEZABY is the first and only product approved by the US Food and Drug Administration (USFDA) for the treatment of neonatal seizures in term and preterm infants, Sun Pharma said in a regulatory filing.

In September 2022, Medtronic announced the European launch of its Smart MDI system, which combines personalized insulin dosing information from the InPen™ smart insulin pen with the power of predictive glucose alerts from the Guardian™ 4 smart continuous glucose monitoring (CGM) system.

Types Covered:

  • Disposable
  • Reusable

Dosages Covered:

  • Fixed Dosage
  • Variable Dosage
  • Half-Unit Dosage
  • Specialized Dosage
  • Other Dosages

Therapies Covered:

  • Diabetes
  • Growth Hormone
  • Osteoporosis
  • Fertility
  • Arthritis
  • Cancer
  • Multiple Sclerosis
  • Autoimmune Diseases
  • Anaphylaxis
  • Cardiovascular Diseases
  • Other Therapies

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Stores
  • Drug Stores

End Users Covered:

  • Home-care Settings
  • Hospital & Clinics

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pen Injectors Market, By Type

  • 5.1 Introduction
  • 5.2 Disposable
  • 5.3 Reusable

6 Global Pen Injectors Market, By Dosage

  • 6.1 Introduction
  • 6.2 Fixed Dosage
  • 6.3 Variable Dosage
  • 6.4 Half-Unit Dosage
  • 6.5 Specialized Dosage
  • 6.6 Other Dosages

7 Global Pen Injectors Market, By Therapy

  • 7.1 Introduction
  • 7.2 Diabetes
    • 7.2.1 Insulin
    • 7.2.2 Glucagon-Like-Peptide-1 (GLP-1)
  • 7.3 Growth Hormone
  • 7.4 Osteoporosis
  • 7.5 Fertility
  • 7.6 Arthritis
  • 7.7 Cancer
  • 7.8 Multiple Sclerosis
  • 7.9 Autoimmune Diseases
  • 7.10 Anaphylaxis
  • 7.11 Cardiovascular Diseases
  • 7.12 Other Therapies

8 Global Pen Injectors Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Stores
  • 8.5 Drug Stores

9 Global Pen Injectors Market, By End User

  • 9.1 Introduction
  • 9.2 Home-care Settings
  • 9.3 Hospital & Clinics

10 Global Pen Injectors Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AstraZeneca
  • 12.2 Becton, Dickinson and Company
  • 12.3 Merck Group
  • 12.4 Pfizer Inc.
  • 12.5 Eli Lilly and Company
  • 12.6 Novartis AG
  • 12.7 Sanofi
  • 12.8 Novo Nordisk A/S
  • 12.9 Biocon
  • 12.10 Medtronic
  • 12.11 Terumo Medical Corporation
  • 12.12 Sun Pharmaceutical Industries Limited
  • 12.13 GlaxoSmithKline PLC
  • 12.14 Mylan N.V.
  • 12.15 Novo Nordisk
  • 12.16 Owen Mumford Limited
  • 12.17 Phillips-Medisize

List of Tables

  • Table 1 Global Pen Injectors Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Pen Injectors Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Pen Injectors Market Outlook, By Disposable (2021-2030) ($MN)
  • Table 4 Global Pen Injectors Market Outlook, By Reusable (2021-2030) ($MN)
  • Table 5 Global Pen Injectors Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 6 Global Pen Injectors Market Outlook, By Fixed Dosage (2021-2030) ($MN)
  • Table 7 Global Pen Injectors Market Outlook, By Variable Dosage (2021-2030) ($MN)
  • Table 8 Global Pen Injectors Market Outlook, By Half-Unit Dosage (2021-2030) ($MN)
  • Table 9 Global Pen Injectors Market Outlook, By Specialized Dosage (2021-2030) ($MN)
  • Table 10 Global Pen Injectors Market Outlook, By Other Dosages (2021-2030) ($MN)
  • Table 11 Global Pen Injectors Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 12 Global Pen Injectors Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 13 Global Pen Injectors Market Outlook, By Insulin (2021-2030) ($MN)
  • Table 14 Global Pen Injectors Market Outlook, By Glucagon-Like-Peptide-1 (GLP-1) (2021-2030) ($MN)
  • Table 15 Global Pen Injectors Market Outlook, By Growth Hormone (2021-2030) ($MN)
  • Table 16 Global Pen Injectors Market Outlook, By Osteoporosis (2021-2030) ($MN)
  • Table 17 Global Pen Injectors Market Outlook, By Fertility (2021-2030) ($MN)
  • Table 18 Global Pen Injectors Market Outlook, By Arthritis (2021-2030) ($MN)
  • Table 19 Global Pen Injectors Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 20 Global Pen Injectors Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 21 Global Pen Injectors Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 22 Global Pen Injectors Market Outlook, By Anaphylaxis (2021-2030) ($MN)
  • Table 23 Global Pen Injectors Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 24 Global Pen Injectors Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 25 Global Pen Injectors Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 26 Global Pen Injectors Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 27 Global Pen Injectors Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 28 Global Pen Injectors Market Outlook, By Online Stores (2021-2030) ($MN)
  • Table 29 Global Pen Injectors Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 30 Global Pen Injectors Market Outlook, By End User (2021-2030) ($MN)
  • Table 31 Global Pen Injectors Market Outlook, By Home-care Settings (2021-2030) ($MN)
  • Table 32 Global Pen Injectors Market Outlook, By Hospital & Clinics (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.